Vulvar Cancer
Methodology & AI Transparency ⓘ
Vulvar Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Vulvar cancer is a rare type of cancer.
- 2 Real-world patient consensus: Clinical coding for Vulvar Cancer uses ICD-10 C51.9 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Primary evaluation for Vulvar Cancer incorporates immunohistochemistry [Vulvar Cancer C51.9] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Vulvar Cancer monitoring tracks Comprehensive Metabolic & in Vulvar Cancer (C51.9: Organ Function Panel) toward Preserved renal/hepatic clearance (C51.9).
Ask our AI Specialists anything about Vulvar Cancer
What Is Vulvar Cancer?
Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Vulvar Cancer (C51.9) center on potential lymphatic or in Vulvar Cancer (C51.9: hematogenous dissemination if). Cross-referenced with NIH MeSH (Vulvar Neoplasms), targeted cancer & oncology interventions aim to normalize Comprehensive Metabolic & in Vulvar Cancer (C51.9: Organ Function Panel).
Common Symptoms & Clinical Signs
- • A lump in the vulva
- • Vulvar itching or tenderness
- • Presentation of Vulvar Cancer (C51.9): unexplained bleeding, chronic in Vulvar Cancer (C51.9: hoarseness/cough, or progressive)
- • Secondary Vulvar Cancer clinical sign: abnormality detected early in Vulvar Cancer (C51.9: on age-appropriate screening)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vulvar Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C51.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Vulvar Cancer (C51.9: Organ Function Panel) | Preserved renal/hepatic clearance (C51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Vulvar Cancer (C51.9: Genomic Staging) | Guideline-concordant surveillance (C51.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Vulvar Cancer (C51.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C51.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vulvar Cancer
Treatment selection for Vulvar Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vulvar Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter: What a 8,916-Participant Study Found RS is an independent measure for BCSS and recurrence prognoses relative to OS in early-stage breast cancer. Journal of the National Comprehensive Cancer Network : JNCCN • 2024-07-17 • Phase III Randomized Trial | N = 8,916 | 90/100 | PMID 39019060 ↗ |
| New Insights on Tislelizumab versus chemotherapy as second-line treatment of advanced or: What a 256-Participant Study Found HRQoL, including fatigue symptoms and physical functioning, was maintained in patients with advanced or metastatic ESCC receiving tislelizumab compared with ICC-treated patients. ESMO open • 2022-08-15 • Phase III Randomized Trial | N = 256 | 87/100 | PMID 35785595 ↗ |
| New Insights on Molecular profile-based recommendations for postoperative add-on treatment in: What a 590-Participant Study Found Secondary outcomes are relapse-free survival, overall survival, side effects and health-related cancer-specific quality of life. Journal of gynecologic oncology • 2023-03-15 • Phase III Randomized Trial | N = 590 | 87/100 | PMID 36659832 ↗ |
| New Insights on Quality of life after simultaneously integrated boost with intensity-modulated: What a 502-Participant Study Found This is the first randomized phase III trial demonstrating that IMRT-SIB was associated with slightly. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2021-10-15 • Phase III Randomized Trial | N = 502 | 87/100 | PMID 34480960 ↗ |
| Can This Approach Help? Inside the Latest Research on Risk factors for recurrence of vulvar high-grade squamous intra-epithelial Applied to the skin imiquimod and surgical treatment of vulvar HSIL are effective in long-term follow-up, with recurrences occurring in 20% to 33% of patients within 5 years. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society • 2026-04-15 • Phase III Randomized Trial | N = 80 | 82/100 | PMID 41791272 ↗ |
Vulvar Cancer Patient Community & “People Like Me” Threads
Filter Vulvar Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.